atai Life Sciences to Participate in Upcoming April Investor Conference
April 19 2022 - 12:26PM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, will participate in the following upcoming
investor conference in April:
- Benzinga Psychedelics ConferenceFormat:
Company Presentation – In Person & VirtualDate and Time:
Tuesday, April 19th, 1:10 p.m. ET – 1:40 p.m. ETConference Link:
URL
The presentation and archived webcast will also be accessible in
the Events section of atai’s website.
About atai Life Sciences atai is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. atai was founded in 2018 as a
response to the significant unmet need and lack of innovation in
the mental health treatment landscape. atai is dedicated to
acquiring, incubating and efficiently developing innovative
therapeutics to treat depression, anxiety, addiction, and other
mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. atai has
offices in New York, Boston, London, and Berlin. For more
information, please visit www.atai.life.
Forward-Looking Statements
This presentation may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. We intend such forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “anticipate,” “initiate,”
“could,” “would,” “project,” “plan,” “potentially,” “preliminary,”
“likely,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these words. All statements contained in this
presentation other than statements of historical fact, including
statements regarding our future operating results and financial
position, the success, cost and timing of development of our
product candidates, including the progress of preclinical studies
and clinical trials and related milestones, the commercialization
of our current product candidates and any other product candidates
we may identify and pursue, if approved, including our ability to
successfully build a specialty sales force and commercial
infrastructure to market our current product candidates and any
other product candidates we may identify and pursue, the timing of
and our ability to obtain and maintain regulatory approvals, our
business strategy and plans, potential acquisitions, and the plans
and objectives of management for future operations and capital
expenditures, are forward-looking statements. Any forward-looking
statements in this presentation are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties, and other factors, many of which are beyond
our control and which could cause actual results, levels of
activity, performance or achievements to differ materially from
those expressed or implied by these forward-looking statements.
We have based any forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions, including without limitation: statements regarding our
future operating results and financial position, the success, cost
and timing of development of our product candidates, including the
progress of preclinical studies and clinical trials and related
milestones, the commercialization of our current product candidates
and any other product candidates we may identify and pursue, if
approved, including our ability to successfully build a specialty
sales force and commercial infrastructure to market our current
product candidates and any other product candidates we may identify
and pursue, the timing of and our ability to obtain and maintain
regulatory approvals, our business strategy and plans, potential
acquisitions, and the plans and objectives of management for future
operations and capital expenditures. Other risk factors include the
important factors described in the section titled “Risk Factors” in
our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission (“SEC”), as updated by our
subsequent filings with the SEC, that may cause our actual results,
performance or achievements to differ materially and adversely from
those expressed or implied by the forward-looking statements.
Any forward-looking statements made herein speak only as of the
date of this presentation, and you should not rely on
forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
the future results, performance, or achievements reflected in the
forward-looking statements will be achieved or will occur. Except
as required by applicable law, we undertake no obligation to update
any of these forward-looking statements for any reason after the
date of this presentation or to conform these statements to actual
results or revised expectation.
Contact Information
Investor Contact:Greg WeaverChief Financial Officer, atai Life
SciencesEmail: IR@atai.life
Media Contact:Maggie GordonSenior Manager, Communications, atai
Life SciencesEmail: maggie@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Sep 2023 to Sep 2024